TABLE 2.
Characteristics of lung transplant recipients throughout the COVID-19 pandemic
| Characteristic | Wave 1 | Wave 2 | Wave 3 | Overall P |
|---|---|---|---|---|
| March–May (N = 431) | June–September (N = 871) | October–December (N = 638) | ||
| Age (y), % | 0.3 | |||
| 0–17 | 0.7 | 1.5 | 1.4 | |
| 18–34 | 7.9 | 5.3 | 4.2 | |
| 35–49 | 10 | 10.3 | 9.9 | |
| 50–64 | 45 | 46.2 | 45.1 | |
| ≥65 | 36.4 | 36.7 | 39.3 | |
| Female sex, % | 43.2 | 42.6 | 40.3 | 0.6 |
| Race, % | 0.6 | |||
| White | 75.9 | 74.7 | 75.1 | |
| Black | 10.2 | 11 | 9.2 | |
| Hispanic/Latino | 11.1 | 9.8 | 11.6 | |
| Other | 2.8 | 4.5 | 4.1 | |
| History of cigarette use, % | 54.5 | 58.4 | 57.2 | 0.4 |
| Insurance, % | 0.4 | |||
| Private | 42.2 | 38.7 | 40.9 | |
| Public | 57.1 | 60.8 | 58 | |
| Other | 0.7 | 0.5 | 1.2 | |
| Primary ESLD diagnosis, % | 0.07 | |||
| A: Obstructive lung disease | 27.6 | 26.5 | 23 | |
| B: Pulmonary vascular disease | 7 | 6.3 | 6.6 | |
| C: Cystic fibrosis | 4.6 | 2.5 | 2 | |
| D: Restrictive lung diseases | 60.8 | 64.6 | 68.3 | |
| LAS, % | 0.4 | |||
| 0–33 | 17.2 | 19.4 | 17 | |
| 34–37 | 22.5 | 21.2 | 23.7 | |
| 38–45 | 22.3 | 22.8 | 26.5 | |
| 46–100 | 38.1 | 36.5 | 32.9 | |
| Time to transplant (mo), (median) IQR | 1.5 (0.4, 4.6) | 1.2 (0.3, 4.7) | 0.9 (0.3, 2.8) | 0.007 |
| Single-lung transplant, % | 20.6 | 19.6 | 25.1 | 0.03 |
COVID-19, coronavirus disease 2019; ESLD, end-stage lung disease; IQR, interquartile range; LAS, lung allocation score.